Loading…
← CockpitCompetitor Analysis › 003020.SZ Hefei Lifeon Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hefei Lifeon Pharmaceutical Co., Ltd. Class A003020.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 40
Mkt cap
$486M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$5.87M
20-day average traded
Fwd P/E
18.2×
forward earnings
ROIC−WACC
+4.4 pp
WACC 5.4%
Hurdle
n/a
no reverse DCF
Next earnings
153 days
20 Apr 2027
Close · CNYCN¥14.27
1D-1.8%
1W-6.7%
1M-12.6%
3M-23.3%
6M-21.2%
YTD-33.8%
1Y-40.5%
ATR %3.6%
52w lowhigh47.2% off high

What Hefei Lifeon Pharmaceutical does

Employees: 1,465

Hefei Lifeon Pharmaceutical at a glance

Size Hefei Lifeon Pharmaceutical (003020.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $486M, the 3767th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.27 on 18 Nov 2026.

Performance Over six months the shares fell 21.2%, against -13.3% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 0.6% over the last twelve months (peer median +11.2%); the operating margin is 10.0% (peer median 8.8%).

Valuation It trades at 18.2× forward earnings against a peer median of 21.3× (3rd cheapest of 6).

Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).

Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 86003020.SZ 81
Six months, rebased to 100: Hefei Lifeon Pharmaceutical against the median of its 20 peers (local-currency closes).

Hefei Lifeon Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.46BCN¥1.54BCN¥1.50BCN¥1.88BCN¥2.56B
Revenue growth—+2%-20%-27%—
Gross profitCN¥1.00BCN¥955MCN¥1.00BCN¥944MCN¥932M
EBITDAn/aCN¥228MCN¥238MCN¥254MCN¥233M
Net incomeCN¥153MCN¥165MCN¥161MCN¥227MCN¥209M
Free cash flow-CN¥439MCN¥119MCN¥48.9MCN¥132M-CN¥8.40M
Capital expenditureCN¥105MCN¥118MCN¥154MCN¥198MCN¥246M
Total debtCN¥132MCN¥114MCN¥128MCN¥109MCN¥254M

Quarterly statements and history in the cockpit →

Hefei Lifeon Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%3005843012771666688373002107RGNXHNSAAARTIDRUGS600624003090600513TKNOSMSPHARMA600222AQSTGYRE37053012016620003020.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hefei Lifeon Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%20×40×1666AARTIDRUGS003090SMSPHARMA6620003020.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hefei Lifeon Pharmaceutical is the large dot.

Hefei Lifeon Pharmaceutical competitors and peer comparison

How Hefei Lifeon Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hefei Lifeon Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure003020.SZPeer medianRank in peer set
1-month return-12.6%-3.9%7th lowest of 21
6-month return-21.2%-13.3%7th lowest of 21
Distance from 52-week high-47.2%-35.5%7th lowest of 21
Revenue growth (TTM)-0.6%+11.2%8th lowest of 21
Operating margin10.0%8.8%11th highest of 21
Forward P/E18.2×21.3×3rd cheapest of 6
ROIC minus cost of capital+4.4 pp-3.0 pp6th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%7.3×-17.2%+6.3%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%n/a5.9%-4.1%
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%21.3×22.1%+3.5%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%4.1×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%n/an/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%n/an/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%n/a16.7%+4.4%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%n/an/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%n/an/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%n/a-3.8%+0.7%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%n/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%n/a-5.4%+7.6%
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%24.9×24.8%+126.7%

Questions

Which companies are Hefei Lifeon Pharmaceutical's closest peers?
The cockpit's peer set: Nanjing Hicin Pharmaceutical (300584.SZ), Newland Pharmaceutical (301277.SZ), Tong Ren Tang Technologies (1666.HK), Shanghai MicuRx Pharmaceutical (688373.SS), Shandong Wohua Pharmaceutical (002107.SZ), REGENXBIO (RGNX), Hansa Biopharma (HNSA.ST), Aarti Drugs (AARTIDRUGS.NS).
Is Hefei Lifeon Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 18.2× against a peer median of 21.3×, 3rd cheapest of 6 in its peer set.
How has Hefei Lifeon Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -21.2% against -13.3% for the median peer; over one year -40.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.